Catalysts for Sandoz Inc
291 tracked
Apr 10, 2026
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Apr 10, 2026
approval
METHYLPREDNISOLONE ACETATE — FDA approval
METHYLPREDNISOLONE ACETATE
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 2, 2026
approval
NINTEDANIB ESYLATE — FDA approval
Ofev
→
Feb 12, 2026
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Feb 12, 2026
approval
ENZEEVU (AFLIBERCEPT-ABZV) — FDA approval
aflibercept biosimilar
→
Feb 12, 2026
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Feb 3, 2026
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Feb 2, 2026
approval
TYRUKO (NATALIZUMAB-SZTN) — FDA approval
natalizumab biosimilar
→
Jan 30, 2026
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Jan 27, 2026
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Jan 21, 2026
approval
MICAFUNGIN SODIUM — FDA approval
Sandoz Inc
→
Jan 20, 2026
approval
METHYLPREDNISOLONE ACETATE — FDA approval
METHYLPREDNISOLONE ACETATE
→
Jan 20, 2026
approval
METHYLPREDNISOLONE ACETATE — FDA approval
METHYLPREDNISOLONE ACETATE
→
Jan 14, 2026
approval
SITAGLIPTIN PHOSPHATE — FDA approval
SITAGLIPTIN PHOSPHATE
→
Jan 5, 2026
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Dec 17, 2025
approval
GABAPENTIN — FDA approval
GABAPENTIN
→
Dec 15, 2025
approval
PEMETREXED DISODIUM — FDA approval
Alimta
→
Dec 2, 2025
approval
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) — FDA approval
metformin hydrochloride ER
→
Nov 24, 2025
approval
ONDANSETRON — FDA approval
Sandoz Inc
→
Nov 21, 2025
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Nov 17, 2025
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Nov 13, 2025
approval
ONDANSETRON — FDA approval
Sandoz Inc
→
Nov 13, 2025
approval
ONDANSETRON — FDA approval
Sandoz Inc
→
Nov 6, 2025
approval
BUPROPION HYDROCHLORIDE — FDA approval
BUPROPION HYDROCHLORIDE
→
Oct 30, 2025
approval
TYRUKO (NATALIZUMAB-SZTN) — FDA approval
natalizumab biosimilar
→
Oct 29, 2025
approval
JUBBONTI (DENOSUMAB-BBDZ) — FDA approval
JUBBONTI
→
Oct 27, 2025
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Oct 24, 2025
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Oct 16, 2025
approval
HYRIMOZ (ADALIMUMAB-ADAZ) — FDA approval
HYRIMOZ
→